Find Funding Opportunities

The Office of Disease Prevention (ODP) and participating National Institutes of Health (NIH) Institutes, Centers, and Offices (ICs) are issuing this Notice of Special Interest (NOSI) to solicit applications proposing to strengthen the evidence base for preventive screening services where the evidence is lacking, of poor quality, conflicting, or the balance of benefits and harms cannot be determined. This NOSI encourages the development and use of innovative and rigorous methods and approaches to close high priority evidence gaps to elevate screening services to a level suitable for a definitive grade or recommendation. The specific research interests of participating NIH ICs are detailed within.

The Office of Disease Prevention (ODP) and participating National Institutes of Health (NIH) Institutes, Centers, and Offices (ICs) are issuing this Notice of Special Interest (NOSI) to encourage applications proposing to test multilevel strategies and interventions to improve the uptake of evidence-based screening services across the lifespan and in populations including, but not limited to, those experiencing health disparities and those that are underserved. Studies addressing efficacy, effectiveness, dissemination and implementation research, as well as studies seeking to understand and address barriers to screening are encouraged. The specific research interests of participating NIH ICs are detailed within.

The purpose of this limited competition Funding Opportunity Announcement is to allow UDN Clinical Sites that received an NIH award under RFA-RM-17-019 an opportunity to compete for one additional year of NIH funding to: continue their participation in the UDN; establish collaborations and efficient processes with the next phase Data Management and Coordinating Center (DMCC; see: RFA-NS-22-051), enroll and evaluate new participants; and develop further their sustainability plans.

The purpose of this funding opportunity announcement is to encourage collaborations between the life and physical sciences that: 1) apply a multidisciplinary bioengineering approach to the solution of a biomedical problem; and 2) integrate, optimize, validate, translate or otherwise accelerate the adoption of promising tools, methods, and techniques for a specific research or clinical problem in basic, translational, or clinical science and practice. An application may propose design-directed, developmental, discovery-driven, or hypothesis-driven research and is appropriate for small teams applying an integrative approach to increase our understanding of and solve problems in biological, clinical, or translational science.

The purpose of this Notice of Special Interest (NOSI) is to encourage the development and validation of animal models that recapitulate the phenotypic and physiologic characteristics of a defined pain type/indication and/or disease-associated pain condition and endpoints or outcome measures that can be used therein. The goal of this NOSI is to promote a significant improvement in the translational relevance of animal models and/or outcome measures that will be utilized to facilitate future development of non-addictive analgesics. Ideally, models or measures proposed for this NOSI would have the potential to provide feasible and meaningful assessments of efficacy following therapeutic intervention that would be applicable in both preclinical and clinical settings.

The purpose of this funding opportunity announcement is to encourage collaborations between the life and physical sciences that: 1) apply a multidisciplinary bioengineering approach to the solution of a biomedical problem; and 2) integrate, optimize, validate, translate or otherwise accelerate the adoption of promising tools, methods, and techniques for a specific research or clinical problem in basic, translational, or clinical science and practice. An application may propose design-directed, developmental, discovery-driven, or hypothesis-driven research and is appropriate for small teams applying an integrative approach to increase our understanding of and solve problems in biological, clinical, or translational science.

The National Institutes of Health (NIH) Office of Nutrition Research (ONR) and participating NIH Institutes and Centers (ICs) intend to publish a Funding Opportunity Announcement (FOA) for new applications that will support new institutional research training programs (predoctoral, postdoctoral or both) in artificial intelligence (AI) for precision nutrition (AIPrN) that will focus on integration of the domains of precision nutrition, AI including machine learning (ML), systems biology, systems science, Big Data, and computational analytics. The goal is to build a future workforce that will be able to use growing data resources to tackle complex biomedical challenges in nutrition science that are beyond human intuition. It is hoped such research will lead to the development of innovative solutions to combat diet-related chronic diseases within the mission areas of the participating ICs. The vision of the AIPrN training program is to support the development of a diverse research workforce capable who will possess advanced competencies in AI including machine learning and data science analytics to apply to an increasingly complex landscape of Big Data from the molecular, to organismal, to community and societal scales related to nutrition and diet related conditions.

The National Institutes of Health (NIH) HEAL (Helping to End Addiction Long-termSM) Initiative intends to promote a new initiative by publishing a Funding Opportunity Announcement (FOA) soliciting applications for UG3/UH3 phased cooperative research to accelerate implementation of evidence-based, non-opioid interventions for chronic pain management in rural and remote populations. Interventions addressing acute pain in rural and remote populations are also responsive if the acute pain requires the intervention of a health care provider for management, such as acute dental pain or acute low back pain and are likely to recur, become chronic, or escalate to a more serious complication if not managed appropriately. Projects include pragmatic, implementation or hybrid effectiveness-implementation trials to improve pain management and reduce the unnecessary use of opioid medications. Awards made under this FOA will initially support a milestone-driven, planning phase (UG3) of 1 to 2 years, with possible transition to a study conduct phase (UH3) of up to 3-4 years duration (5 years total for the two phases). Only UG3 projects with a planned pilot may request 2 years for the planning phase with up to 3 years for the UH3 implementation phase.in the community. All other projects may request 1 year for the UG3 phase with up to 4 years for the UH3 phase. UG3 projects that have met the scientific milestone and feasibility requirements may transition to the UH3 phase.

This Notice of Special Interest is a reissue of NOT-MD-19-001 Notice of Special Interest in Research on the Health of Sexual and Gender Minority (SGM) Populations. The reissue includes updates of programmatic interest for NHGRI, NIA, NIDCR, NIDDK, and ORWH, and updated Scientific Contacts.

This BRAIN Initiative FOA is to further develop molecular tools of high impact that are targetable to brain cell types for the monitoring and manipulation of neural circuits in experimental animals. This FOA is part of the BRAIN Initiative Armamentarium for Brain Cell Access transformative project. This will support iterative improvement of molecular payloads capable of monitoring and manipulating neural cell activity and that can be delivered to specific brain cell types using targeting technologies.